- Home
- SM vs QGEN Comparison
SM vs QGEN Comparison
Compare SM & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SM | QGEN |
|---|---|---|
| Founded | 1908 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 9.0B |
| IPO Year | 1996 | 1998 |
Fundamental Metrics
Financial Performance| Metric | SM | QGEN |
|---|---|---|
| Price | $35.10 | $44.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 8 |
| Target Price | $34.36 | ★ $45.76 |
| AVG Volume (30 Days) | ★ 3.7M | 1.6M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | 2.56% | ★ 7.17% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.34 | N/A |
| Revenue | ★ $3,154,000,000.00 | N/A |
| Revenue This Year | $129.01 | $8.18 |
| Revenue Next Year | $6.29 | $5.71 |
| P/E Ratio | ★ $10.27 | $24.01 |
| Revenue Growth | ★ 17.24 | N/A |
| 52 Week Low | $17.45 | $32.53 |
| 52 Week High | $41.56 | $57.82 |
Technical Indicators
Market Signals| Indicator | SM | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 45.22 | 55.47 |
| Support Level | $34.48 | $41.34 |
| Resistance Level | $35.88 | $44.45 |
| Average True Range (ATR) | 1.24 | 0.84 |
| MACD | -0.69 | 0.07 |
| Stochastic Oscillator | 13.12 | 76.62 |
Price Performance
Historical ComparisonAbout SM SM Energy Company
SM Energy Co is an independent energy company engaged in the acquisition, exploration, development, and production of oil, gas, and NGLs in Texas and Utah. The Company operates in the oil and gas extraction industry, focused on exploration and production activities, onshore in the United States. Its portfolio is comprised of assets in the Midland Basin of West Texas, the Maverick Basin of South Texas, and the Uinta Basin of northeastern Utah.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).